Pneumococcal vaccine polyvalent

(Pneumovax 23®)

Pneumococcal vaccine polyvalent

Drug updated on 11/4/2024

Dosage FormInjection (subcutaneous; 0.5 mL in single-dose vial)
Drug ClassVaccines
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated for active immunization for the prevention of pneumococcal disease caused by the 23 serotypes contained in the vaccine (1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, and 33F)

Latest News

loading GIF

Summary
This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

  • This summary is based on the review of one systematic review(s)/meta-analysis(es). [1]
  • Welders exhibited a statistically significant increase in the likelihood of developing invasive pneumococcal disease (IPD) compared to non-welders, with an odds ratio of 2.59 (95% CI (confidence interval) 2.00-3.35).
  • The standardized mortality ratio (SMR) for welders dying from IPD was 2.42 (95% CI 1.96-2.99).
  • Among 72 IPD cases, serotype 4 was most prevalent (60.3%), followed by serotype 12F (19.2%) and serotype 8 (8.2%), which may influence vaccine effectiveness based on targeted serotype coverage.
  • Welders and workers exposed to welding fumes and metal dusts show a significantly increased risk of developing and dying from invasive pneumococcal disease (IPD), with an odds ratio of 2.59 (95% CI 2.00-3.35) for developing IPD and a standardized mortality ratio (SMR) of 2.42 (95% CI 1.96-2.99) for mortality, suggesting the importance of targeted vaccination. Serotype distribution (serotype 4 at 60.3%, serotype 12F at 19.2%, and serotype 8 at 8.2%) may inform vaccination strategies for these occupational groups.